Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 22Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 6Lung Neoplasms 6Brain Neoplasms 6Colorectal Neoplasms 5Skin Neoplasms 4Neoplasms 4Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Breast Neoplasms 3Uveal Melanoma 2Multiple Myeloma 2Lymphoma 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Glioma 2Endometrial Neoplasms 2Colonic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Solid Tumors 1Soft Tissue Neoplasms 1Skin Diseases 1Rectal Neoplasms 1

Interventions

binimetinib 1belinostat 1Vincristine 1Topotecan 1Lasers 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Eye Enucleation 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Eye Neoplasms × binimetinib × 1 year × Clear all
NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
7 enrolled
Dermatologic

Uveal Melanoma, Eye Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡